Healthcare News

Mechelen, België; 13 juli 2026, 22:01 CET; Lakefront Biotherapeutics NV (Euronext & NASDAQ: LKFT) heeft vandaag bekendgemaakt dat dr. Paulo Fontoura, na zijn benoeming tot Executive Vice President...

At RDE of 32 mg QD, encouraging monotherapy responses with 57% uORR in 2L+ KRAS G12X pancreatic cancer in U.S. trial and median relative dose intensity of 100% Monotherapy has been generally...

Cosmos Health has now repurchased a total of 4,355,000 shares for approximately $901,000.

Cosmos Health accelerates prescription medicine strategy with Libytec partnership to commercialize DIABIT-IS X in Greece.

這項全國計劃會採用 Alamar Biosciences 的 NULISAseq™ Neuro 220 多重檢測組合試劑盒，分析來自 10,000 名阿茲海默症及相關認知障礙症 (ADRD) 參與者約 21,000 份的血漿樣本。 研究所得的數據集將全面開放，經由 National Alzheimer’s Coordinating Center...

这项全国性研究计划将利用 Alamar Biosciences 的 NULISAseq™ Neuro 220 检测试剂盒，对 10,000 名阿尔茨海默病及相关痴呆症 (ADRD) 受试者提供的约 21,000 万份血浆样本开展图谱分析。 生成的数据集将对外开放，可通过 National Alzheimer’s Coordinating Center (美国国家阿尔茨海默病协调中心)...

First patient dosed with ZI-MA4-1 in the ZIMA-101 Phase 1 trial at The Christie NHS Foundation TrustZI-MA4-1 is the world’s first MAGE-A4-targeting TCR-NK therapy in clinical developmentZIMA-101...

Første pasient dosert med ZI-MA4-1 ved The Christie NHS Foundation Trust. ZI-MA4-1 er verdens første MAGE-A4-rettede TCR-NK-terapi som nå testes i pasienter for første gangMed ZIMA-101 testes...

Company announcement No. 32 / 2026 Zealand Pharma - Transactions related to share buy-back program (week 28, 2026) Copenhagen, Denmark, July 13, 2026 – Zealand Pharma A/S ("the Company" or “Zealand...

MARKHAM, Ontario, July 13, 2026 (GLOBE NEWSWIRE) -- Sienna Senior Living Inc. ("Sienna" or the "Company") is proud to announce it has been named one of Canada's Best Companies by TIME and Statista...